Article:
Makris, M. orcid.org/0000-0001-7622-7939 and Farrugia, A. (2019) Comparative analysis of marketed factor VIII products: comment. Journal of Thrombosis and Haemostasis, 17 (1). pp. 232-233. ISSN 1538-7933

https://doi.org/10.1111/jth.14321

We read with interest the paper by Azengruber and colleagues recently published in the journal. The authors reported significant variation among the different recombinant concentrates in terms of content of soluble protein aggregates and subvisible particles(1). This could be important in explaining the differential immunogenicity, in terms of inhibitor development, among recombinant concentrates.

We were, however, disappointed that the authors do not name the nine brands of recombinant FVIII concentrates they studied. By convention in scientific literature, authors are required to name their reagents and their source. We can not see any reason why the names of the concentrates were withheld and invite the authors to name the products now. This is particularly relevant as the studies cited by Anzengruber et al to demonstrate the different rates of inhibitor incidence relative to product type do cite the products used (2), (3). A similar level of disclosure would have enhanced the relevance of Anzengruber et al's study and contributed to guiding therapeutic choice.

Without naming the products, all one can conclude is that there is variation between the products but by naming them the scientific community can correlate the results with other observations about specific concentrates. We note that, in order to differentiate their particular products and leverage market advantage, some products are acquiring approval from regulatory agencies by validating conditions, including storage at room temperature (4), which may well precipitate the kind of environmental pressure which generates the changes reported by Anzengruber et al (5). It would seem that the kind of analytes studied in their paper should be considered for the purpose of product quality control, but for this to be considered by authorities full information is required.

Mike Makris
Professor of Haemostasis and Thrombosis, University of Sheffield

Albert Farrugia
Adjunct Professor, School of Surgery, University of Western Australia

References:

1. Anzengruber J, Lubich C, Prenninger T, Gringeri A, Scheiflinger F, Reipert BM, Malisauskas M. Comparative analysis of marketed factor VIII products: recombinant products are not alike vis-a-vis soluble protein aggregates and subvisible particles. J Thromb Haemost. 2018; 16:1176–81.

2. Gouw SC, van der Bom JG, Ljung R, Escuriola C, Cid AR, Claeyssens-Donadel S, van Geet C, Kenet G, Makipernaa A, Molinari AC, Muntean W, Kobelt R, Rivard G, Santagostino E, Thomas A, van den Berg HM. Factor VIII products and inhibitor development in severe hemophilia A. N Engl J Med. 2013; 368:231–9.

3. Calvez T, Chambost H, Claeyssens-Donadel S, d'Oiron R, Goulet V, Guillet B, Heritier V, Milien V, Rothchild C, Roussel-Robert V, Vinciguerra C,

Goudemand J. Recombinant factor VIII products and inhibitor development in previously untreated boys with severe hemophilia A. Blood. 2014; 124:3398–408.

4. Frase M. Safely Storing Factor at Home. HemAware. 2010 [cited 2018 Jul 9]. Available from: https://hemaware.org/bleeding-disorders-z/safely-storing-factor-home

5. Roberts CJ. Therapeutic Protein Aggregation: Mechanisms, Design, and Control. Trends Biotechnol. 2014; 32:372–80.

Disclosure of conflict of interest

MM has acted as consultant or participated in advisory panels for Bioverativ, CSL Behring, NovoNordisk and Shire. MM is also the project leader for EUHASS which receives funding from Bayer, Biotest, BPL, CSL Behring, Grifols, Kedrion, LFB, NovoNordisk, Octapharma, Pfizer, Roche, Shire and Sobi

AF provides compensated consultancy services to the manufacturers of Factor VIII concentrates.